Product information
| Price | €175, €275, €395 |
|---|---|
| Size | 20 µl/µg | 50 µl/µg | 100 µl/µg |
| Short name | SSX Antibody |
| Host | Rabbit |
| Isotype | IgG |
| Target protein | SSX1 |
| Recommended applications | ELISA, IHC-p, WB |
| Reactivity | Human |
| Immunogen | The antiserum was produced against synthesized peptide derived from the C-terminal region of human SSX1/2/3/4/5/6/7/8/9. AA range:139-188 |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Formulation | Liquid in PBS containing 50% glycerol; 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Product code | MB-AP14112 |
Additional information
Prev
Next
The product of SSX1 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX2 and SSX4 family members, have been involved in t(X;18)(p11. ;q11. ) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome X.
SSX1, Protein SSX1, Cancer/testis antigen 5.1, CT5.1, Synovial sarcoma, X breakpoint 1, SSX2, SSX2A, SSX2B, Protein SSX2, Cancer/testis antigen 5.2, CT5.2, Synovial sarcoma, X breakpoint 2, Tumor anti
Human: Q16384
Human: 6756
